BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 30937974)

  • 1. Costunolide enhances sensitivity of K562/ADR chronic myeloid leukemia cells to doxorubicin through PI3K/Akt pathway.
    Cai H; Li L; Jiang J; Zhao C; Yang C
    Phytother Res; 2019 Jun; 33(6):1683-1688. PubMed ID: 30937974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costunolide promotes imatinib-induced apoptosis in chronic myeloid leukemia cells via the Bcr/Abl-Stat5 pathway.
    Cai H; He X; Yang C
    Phytother Res; 2018 Sep; 32(9):1764-1769. PubMed ID: 29701267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timosaponin A-III reverses multi-drug resistance in human chronic myelogenous leukemia K562/ADM cells via downregulation of MDR1 and MRP1 expression by inhibiting PI3K/Akt signaling pathway.
    Chen JR; Jia XH; Wang H; Yi YJ; Wang JY; Li YJ
    Int J Oncol; 2016 May; 48(5):2063-70. PubMed ID: 26984633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Costunolide Induces Apoptosis of K562/ADR Cells through PI3K/AKT Pathway].
    Cai H; Hu H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):68-71. PubMed ID: 33554799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Critical Role of PTEN/PI3K/AKT Signaling Pathway in Shikonin-Induced Apoptosis and Proliferation Inhibition of Chronic Myeloid Leukemia.
    Chen Y; Wang T; Du J; Li Y; Wang X; Zhou Y; Yu X; Fan W; Zhu Q; Tong X; Wang Y
    Cell Physiol Biochem; 2018; 47(3):981-993. PubMed ID: 29843123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silencing of the CrkL gene reverses the doxorubicin resistance of K562/ADR cells through regulating PI3K/Akt/MRP1 signaling.
    Yu J; Chen WX; Xie WJ; Chen RW; Lin DQ; You WW; Ye WL; Zhang HQ; Lin DH; Xu JP
    J Clin Lab Anal; 2021 Aug; 35(8):e23817. PubMed ID: 34114685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
    Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
    Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of miR-181c inhibits chemoresistance by targeting ST8SIA4 in chronic myelocytic leukemia.
    Zhao L; Li Y; Song X; Zhou H; Li N; Miao Y; Jia L
    Oncotarget; 2016 Sep; 7(37):60074-60086. PubMed ID: 27527856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
    Zhao L; Shan Y; Liu B; Li Y; Jia L
    Cell Death Dis; 2017 May; 8(5):e2830. PubMed ID: 28542127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resveratrol Increases Anti-Proliferative Activity of Bestatin Through Downregulating P-Glycoprotein Expression Via Inhibiting PI3K/Akt/mTOR Pathway in K562/ADR Cells.
    Wang L; Wang C; Jia Y; Liu Z; Shu X; Liu K
    J Cell Biochem; 2016 May; 117(5):1233-9. PubMed ID: 26460589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
    Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
    Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells.
    Zhong J; Zhang J; Yu X; Zhang X; Dian L
    Med Sci Monit; 2020 Aug; 26():e924922. PubMed ID: 32830792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
    Wang CG; Zhong L; Liu YL; Shi XJ; Shi LQ; Zeng L; Liu BZ
    Integr Cancer Ther; 2017 Dec; 16(4):526-539. PubMed ID: 27698265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
    Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
    Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alantolactone inhibits growth of K562/adriamycin cells by downregulating Bcr/Abl and P-glycoprotein expression.
    Yang C; Yang J; Sun M; Yan J; Meng X; Ma T
    IUBMB Life; 2013 May; 65(5):435-44. PubMed ID: 23441067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
    Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
    Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-κB and disruption of mitochondria-dependent pathways.
    Wang R; Shao F; Liu Z; Zhang J; Wang S; Liu J; Liu H; Chen H; Liu K; Xia M; Wang Y
    Chem Biol Interact; 2013 Sep; 205(1):1-10. PubMed ID: 23777986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.